- A novel method to diagnose COVID-19 and severity using low-density inflammatory band cells (LDIBS) associated with coagulopathy;
- Could be used as an adjunct clinical biomarker for COVID-19 disease status and progression;
- Could aid in earlier diagnosis and subsequent treatment of COVID-19.
Approximately 20% of COVID-19 infected patients experience a severe manifestation of the disease. These severe cases often have pronounced coagulopathy (excessive bleeding/clotting) with approximately 30% of patients experiencing thromboembolic complications. However, the underlying causes driving the coagulopathy remains unknown. Identification of these causes would further aid clinicians in diagnosing and treating COVID-19.
To solve this problem, researchers at the University of Louisville have developed a novel method to identify low-density inflammatory band cells (LDIBs) associated with coagulopathy and use them as a clinical biomarker in diagnosing COVID-19 and its severity
Determined to contribute to COVID-19-associated coagulopathy (CAC), these LDIBs could be used as an adjunct clinical marker to monitor disease status and progression.
This biomarker may aid in identifying patients who are trending towards LDIB crisis, as well as aid in the early implementation of appropriate treatments which could thus improve mortality rates for severe COVID-19 patients